<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cb44b-a374-70ca-b242-05d0124c5e9f,g:0717f2d3-70e4-403c-8fbf-c5ceb6f1c9cc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhvn-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cb44b-a4d4-7878-8cf1-5d990e416d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cb44b-a4d4-79cf-8a39-c2f6f814d32c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cb44b-a4d4-7878-8cf1-5d990e416d79" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cb44b-a4d4-79cf-8a39-c2f6f814d32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cb44b-a4d4-769c-9eef-13839d8e9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cb44b-a4d4-7878-8cf1-5d990e416d79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019cb44b-a4d4-769c-9eef-13839d8e9ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019cb44b-a4d4-7410-beaa-61fd0b58a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cb44b-a4d4-7878-8cf1-5d990e416d79" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019cb44b-a4d4-7410-beaa-61fd0b58a4b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_019cb44b-a4d4-7d67-83f2-e9ed9945accd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019cb44b-a4d4-7878-8cf1-5d990e416d79" xlink:to="loc_us-gaap_LongTermNotesPayable_019cb44b-a4d4-7d67-83f2-e9ed9945accd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cb44b-a4d4-70bb-aeeb-60b521e85e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019cb44b-a4d4-70c6-9bfc-d65d6a99103f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cb44b-a4d4-70bb-aeeb-60b521e85e3b" xlink:to="loc_us-gaap_Liabilities_019cb44b-a4d4-70c6-9bfc-d65d6a99103f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cb44b-a4d4-772a-a354-b7515307128a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cb44b-a4d4-70bb-aeeb-60b521e85e3b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cb44b-a4d4-772a-a354-b7515307128a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-72e3-991d-8030b5e791c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cb44b-a4d4-70bb-aeeb-60b521e85e3b" xlink:to="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-72e3-991d-8030b5e791c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7f35-a19e-474d58c310bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:to="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7f35-a19e-474d58c310bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019cb44b-a4d4-73f9-88fa-8ea96499bbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:to="loc_us-gaap_Goodwill_019cb44b-a4d4-73f9-88fa-8ea96499bbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cb44b-a4d4-7f92-ad87-1bf8cf61fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cb44b-a4d4-7f92-ad87-1bf8cf61fff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019cb44b-a4d4-79b2-a9fe-e99a030086cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019cb44b-a4d4-79b2-a9fe-e99a030086cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cb44b-a4d4-7b22-b043-be4daee8761e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cb44b-a4d4-7597-bc54-d72e58be6d88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cb44b-a4d4-7b22-b043-be4daee8761e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7202-833b-8e52e0088547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019cb44b-a4d4-7901-9725-f922e6396a21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7202-833b-8e52e0088547" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019cb44b-a4d4-7901-9725-f922e6396a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019cb44b-a4d4-7c60-a03f-c388d0596fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7202-833b-8e52e0088547" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019cb44b-a4d4-7c60-a03f-c388d0596fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cb44b-a4d4-7941-b782-a2aaca3b376f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7202-833b-8e52e0088547" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cb44b-a4d4-7941-b782-a2aaca3b376f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019cb44b-a4d4-79bd-bed5-1edcd446a98b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cb44b-a4d4-7202-833b-8e52e0088547" xlink:to="loc_us-gaap_OtherAssetsCurrent_019cb44b-a4d4-79bd-bed5-1edcd446a98b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019cb44b-a4d4-7f62-829c-50c5940ea95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:to="loc_us-gaap_PreferredStockValue_019cb44b-a4d4-7f62-829c-50c5940ea95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cb44b-a4d4-7aaa-b384-5844ac1c1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cb44b-a4d4-7aaa-b384-5844ac1c1f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019cb44b-a4d4-7f83-b5fd-947fd27315d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019cb44b-a4d4-7f83-b5fd-947fd27315d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cb44b-a4d4-7e3e-95fc-e4b3cd488199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:to="loc_us-gaap_CommonStockValue_019cb44b-a4d4-7e3e-95fc-e4b3cd488199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cb44b-a4d4-7729-ba37-091c64b7b8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cb44b-a4d4-7c82-8259-2c5d8e05f119" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cb44b-a4d4-7729-ba37-091c64b7b8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cb44b-a4d4-7de2-ac18-0244e3d693ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cb44b-a4d4-7f22-b2da-ee4ebf202b96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cb44b-a4d4-7de2-ac18-0244e3d693ee" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cb44b-a4d4-7f22-b2da-ee4ebf202b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a4d4-78f4-9b8d-264da51419d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cb44b-a4d4-7de2-ac18-0244e3d693ee" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a4d4-78f4-9b8d-264da51419d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhvn-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb44b-a582-74f0-a857-3ff53d6cb72c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cb44b-a582-71e1-aa32-264d9783be41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb44b-a582-74f0-a857-3ff53d6cb72c" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cb44b-a582-71e1-aa32-264d9783be41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cb44b-a582-7201-8287-13792c5b4231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb44b-a582-74f0-a857-3ff53d6cb72c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cb44b-a582-7201-8287-13792c5b4231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cb44b-a582-770f-aa9f-ec97d5a93f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cb44b-a582-7e24-a0f5-1a2cb62fdd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cb44b-a582-770f-aa9f-ec97d5a93f56" xlink:to="loc_us-gaap_NetIncomeLoss_019cb44b-a582-7e24-a0f5-1a2cb62fdd8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cb44b-a582-77d7-9991-659494d40c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cb44b-a582-770f-aa9f-ec97d5a93f56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cb44b-a582-77d7-9991-659494d40c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cb44b-a582-736b-926b-dbfdeb99ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb44b-a582-7cb7-9669-c8373109b9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cb44b-a582-736b-926b-dbfdeb99ef9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb44b-a582-7cb7-9669-c8373109b9fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cb44b-a582-7361-95b7-c03fd1caf83e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cb44b-a582-736b-926b-dbfdeb99ef9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cb44b-a582-7361-95b7-c03fd1caf83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019cb44b-a582-74d9-b188-5e612996d95d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cb44b-a582-7974-a60f-6f2638d56bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019cb44b-a582-74d9-b188-5e612996d95d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cb44b-a582-7974-a60f-6f2638d56bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cb44b-a582-79e9-9fae-4e6ce41d6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019cb44b-a582-74d9-b188-5e612996d95d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cb44b-a582-79e9-9fae-4e6ce41d6a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cb44b-a582-7dc7-a1a7-80b86405ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019cb44b-a582-7cf1-844c-8e31dee7b794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019cb44b-a582-7dc7-a1a7-80b86405ac7f" xlink:to="loc_us-gaap_CostsAndExpenses_019cb44b-a582-7cf1-844c-8e31dee7b794" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhvn-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7826-94b7-71b7db4a1ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cb44b-a582-7939-aef3-a865a0f777b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7826-94b7-71b7db4a1ec1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cb44b-a582-7939-aef3-a865a0f777b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019cb44b-a582-7df7-903f-b25af170fdba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7826-94b7-71b7db4a1ec1" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019cb44b-a582-7df7-903f-b25af170fdba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019cb44b-a582-7945-a122-5217364b491c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7826-94b7-71b7db4a1ec1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019cb44b-a582-7945-a122-5217364b491c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cb44b-a582-74ed-b0f6-09e94ed12e17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_ShareBasedCompensation_019cb44b-a582-74ed-b0f6-09e94ed12e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_019cb44b-a582-7145-8f14-cc6178376987" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_019cb44b-a582-7145-8f14-cc6178376987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019cb44b-a582-76e9-a26c-9f9d2e37aed5" xlink:href="bhvn-20260331.xsd#bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019cb44b-a582-76e9-a26c-9f9d2e37aed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019cb44b-a582-786c-8e07-a3847af84d81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019cb44b-a582-786c-8e07-a3847af84d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cb44b-a582-79f5-981d-9c6622822e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cb44b-a582-79f5-981d-9c6622822e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019cb44b-a582-75c9-92fa-e8fe3d78459d" xlink:href="bhvn-20260331.xsd#bhvn_ChangeInFairValueOfDerivativeLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019cb44b-a582-75c9-92fa-e8fe3d78459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cb44b-a582-7dcf-8bc1-b2bef868df94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_NetIncomeLoss_019cb44b-a582-7dcf-8bc1-b2bef868df94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cb44b-a582-7d4c-b8a9-9871fe3d53cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019cb44b-a582-7d4c-b8a9-9871fe3d53cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cb44b-a582-7eaa-a6ae-a92ae4e73f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019cb44b-a582-7eaa-a6ae-a92ae4e73f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_FairValueAdjustmentOfNotesPayable_019dd9e9-988d-7ab2-8638-5737e2ae6d0f" xlink:href="bhvn-20260331.xsd#bhvn_FairValueAdjustmentOfNotesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7543-a3f7-097fa2683883" xlink:to="loc_bhvn_FairValueAdjustmentOfNotesPayable_019dd9e9-988d-7ab2-8638-5737e2ae6d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7767-a0ac-6251524d6420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cb44b-a582-7f0f-a306-1cb40ab4aefe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7767-a0ac-6251524d6420" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cb44b-a582-7f0f-a306-1cb40ab4aefe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019cb44b-a582-7f83-9904-b269091593b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7767-a0ac-6251524d6420" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019cb44b-a582-7f83-9904-b269091593b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019cb44b-a582-7ea4-819c-519653e31a59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7767-a0ac-6251524d6420" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019cb44b-a582-7ea4-819c-519653e31a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cb44b-a582-76fb-b3bb-507366095b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7439-b903-3619f4d4228e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cb44b-a582-76fb-b3bb-507366095b4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cb44b-a582-7439-b903-3619f4d4228e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7b1f-9728-20dfc03a749f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cb44b-a582-76fb-b3bb-507366095b4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cb44b-a582-7b1f-9728-20dfc03a749f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7716-aa3a-d949932fbd25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cb44b-a582-76fb-b3bb-507366095b4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb44b-a582-7716-aa3a-d949932fbd25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-700b-a48c-22dbc70266d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cb44b-a582-76fb-b3bb-507366095b4a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-700b-a48c-22dbc70266d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-7f8f-beaf-b17bb758c559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cb44b-a582-7634-8b8e-979d8bf3e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-7f8f-beaf-b17bb758c559" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cb44b-a582-7634-8b8e-979d8bf3e00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019cb44b-a582-7176-890a-dd2deec4d502" xlink:href="bhvn-20260331.xsd#bhvn_RestrictedCashIncludedInOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-7f8f-beaf-b17bb758c559" xlink:to="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019cb44b-a582-7176-890a-dd2deec4d502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019cb44b-a582-7721-b736-12b443954ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019cb44b-a582-7f8f-beaf-b17bb758c559" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019cb44b-a582-7721-b736-12b443954ad8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019cb44b-a582-7aa7-bff9-cf3986e310a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cb44b-a582-7a76-812e-dbc4b32b2779" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019cb44b-a582-7aa7-bff9-cf3986e310a0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cb44b-a582-7a76-812e-dbc4b32b2779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cb44b-a582-701a-bae7-1783a2a8605a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019cb44b-a582-7aa7-bff9-cf3986e310a0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cb44b-a582-701a-bae7-1783a2a8605a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cb44b-a582-7f49-8233-619864cc55c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019cb44b-a582-7aa7-bff9-cf3986e310a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cb44b-a582-7f49-8233-619864cc55c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#MarketableSecuritiesNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019cb44b-a582-73ec-8902-ed35dfa9e7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019cb44b-a582-7117-8f7b-ba01efa3f574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019cb44b-a582-73ec-8902-ed35dfa9e7ea" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_019cb44b-a582-7117-8f7b-ba01efa3f574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019cb44b-a582-7d0b-9d57-332fab74b710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019cb44b-a582-73ec-8902-ed35dfa9e7ea" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019cb44b-a582-7d0b-9d57-332fab74b710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019cb44b-a582-766f-805d-d0e120fb4da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019cb44b-a582-76e4-b691-1f977d0e789f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019cb44b-a582-766f-805d-d0e120fb4da6" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019cb44b-a582-76e4-b691-1f977d0e789f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019cb44b-a582-7ffc-85cb-dccfa0a772c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019cb44b-a582-766f-805d-d0e120fb4da6" xlink:to="loc_us-gaap_InterestIncomeOther_019cb44b-a582-7ffc-85cb-dccfa0a772c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cb44b-a582-7baa-b17a-81db4646a25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_019cd684-993c-7fce-bfd0-9e11fb76ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019cb44b-a582-7baa-b17a-81db4646a25e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_019cd684-993c-7fce-bfd0-9e11fb76ee49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cb44b-a582-79fd-b98f-e02dc6cc0677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_019cb44b-a582-7a6c-9553-fbb32a499df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cb44b-a582-79fd-b98f-e02dc6cc0677" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_019cb44b-a582-7a6c-9553-fbb32a499df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb44b-a582-7af5-ac27-5554887f357a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cb44b-a582-79fd-b98f-e02dc6cc0677" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb44b-a582-7af5-ac27-5554887f357a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_019cb44b-a582-7b47-8da9-c44e5ffc4798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cb44b-a582-79fd-b98f-e02dc6cc0677" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_019cb44b-a582-7b47-8da9-c44e5ffc4798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019cd683-ff39-7cb0-a789-a01af953a99e" xlink:href="bhvn-20260331.xsd#bhvn_OtherCurrentAssetsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cb44b-a582-79fd-b98f-e02dc6cc0677" xlink:to="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019cd683-ff39-7cb0-a789-a01af953a99e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cb44b-a582-7155-bf00-70a4baf6d011" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019cb44b-a582-7441-9152-81ca982241c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019cb44b-a582-7155-bf00-70a4baf6d011" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019cb44b-a582-7441-9152-81ca982241c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cb44b-a582-71e5-83e9-68b480440488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019cb44b-a582-7155-bf00-70a4baf6d011" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019cb44b-a582-71e5-83e9-68b480440488" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#BalanceSheetComponentsOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cb44b-a582-71e7-8f80-44bc6687bb14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cb44b-a582-7d13-a91e-87694082110b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019cb44b-a582-71e7-8f80-44bc6687bb14" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019cb44b-a582-7d13-a91e-87694082110b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019cb44b-a582-70ff-b4a6-b733b9dbe5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019cb44b-a582-71e7-8f80-44bc6687bb14" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019cb44b-a582-70ff-b4a6-b733b9dbe5e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhvn-20260331.xsd#BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cb44b-a582-79b6-bec6-7947fe1d1942" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cb44b-a582-79b6-bec6-7947fe1d1942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedClinicalTrialCostsCurrent_019cb44b-a582-73f0-8f3d-0b1c6b4e6f9b" xlink:href="bhvn-20260331.xsd#bhvn_AccruedClinicalTrialCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:to="loc_bhvn_AccruedClinicalTrialCostsCurrent_019cb44b-a582-73f0-8f3d-0b1c6b4e6f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cb44b-a582-767f-8b08-15082428bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cb44b-a582-767f-8b08-15082428bb3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedConsiderationTrueUpLiability_019cb44b-a582-7970-b9fa-70e53a4d8ac5" xlink:href="bhvn-20260331.xsd#bhvn_AccruedConsiderationTrueUpLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:to="loc_bhvn_AccruedConsiderationTrueUpLiability_019cb44b-a582-7970-b9fa-70e53a4d8ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d4794-da00-7dad-87de-a861598e7741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019cb44b-a582-7ebe-a4f8-de6b07106503" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019d4794-da00-7dad-87de-a861598e7741" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
